fda approves empagliflozin use for heart failure despite contrary results of trials
Published 2 years ago • 2.3K plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
2:41
fda approves empagliflozin for reducing kidney disease progression in ckd patients
-
5:07
02.03.2022 top medical news
-
5:10
empagliflozin retains benefits in ‘true’ hfpef patients
-
2:03
empagliflozin (jardiance)- fda approval for kidney disease progression
-
5:14
risk for heart failure modulate the effectiveness of empagliflozin ?
-
6:28
emperor-reduced: empagliflozin benefits in hf patients irrespective of diabetes | milton packer
-
30:29
heart failure spotlight: jardiance® (empagliflozin) tablets: the impact of empa-reg outcome
-
13:17
empagliflozin in heart failure with a preserved ejection fraction
-
8:15
sglt2 inhibitors and heart failure
-
5:21
empulse: the ‘missing link’ for empagliflozin in heart failure | adriaan voors
-
6:14
jardiance or empagliflozin: 9 must know clinical facts including side effects
-
13:01
fda approval of sotagliflozin - inpefa
-
0:55
further research studies of dapagliflozin
-
13:07
nurse webinars - sglt2i - dapagliflozin and empagliflozin
-
10:31
jardiance for heart failure and diabetes: an in-depth summary
-
10:30
ada 2020: findings from empa-reg outcome trial — dr muthiah vaduganathan
-
10:57
best practices for starting sglt2 inhibitors in hfpef treatment
-
2:34
fda approves only type 2 diabetes treatment for cardiovascular use
-
3:35
hf 2022: deliver extends benefits of dapagliflozin to the full spectrum of pts with hf